



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Adenylosuccinic acid

<b>Cat. No.:</b>	HY-127137
<b>CAS No.:</b>	19046-78-7
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>18</sub> N <sub>5</sub> O <sub>11</sub> P
<b>Molecular Weight:</b>	463.29
<b>Target:</b>	Endogenous Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD) <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	Human Endogenous Metabolite								
<b>In Vivo</b>	<p>Adenylosuccinic acid (oral administration; 3-3000 µg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca<sup>2+</sup> content of mdx tibialis anterior<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>3 µg/mL, 30 µg/mL, 300 µg/mL, 3000 µg/mL</td> </tr> <tr> <td>Administration:</td> <td>3 µg/mL for 3 days and 30 µg/mL for the next 4 days, and 300 µg/mL for one week, and then 3000 µg/mL for 6 weeks</td> </tr> <tr> <td>Result:</td> <td>Ameliorated the symptoms of murine duchenne muscular dystrophy.</td> </tr> </table>	Animal Model:	C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice <sup>[1]</sup>	Dosage:	3 µg/mL, 30 µg/mL, 300 µg/mL, 3000 µg/mL	Administration:	3 µg/mL for 3 days and 30 µg/mL for the next 4 days, and 300 µg/mL for one week, and then 3000 µg/mL for 6 weeks	Result:	Ameliorated the symptoms of murine duchenne muscular dystrophy.
Animal Model:	C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice <sup>[1]</sup>								
Dosage:	3 µg/mL, 30 µg/mL, 300 µg/mL, 3000 µg/mL								
Administration:	3 µg/mL for 3 days and 30 µg/mL for the next 4 days, and 300 µg/mL for one week, and then 3000 µg/mL for 6 weeks								
Result:	Ameliorated the symptoms of murine duchenne muscular dystrophy.								

### REFERENCES

[1]. Timpani CA, et al. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy. *Sci Rep.* 2020 Jan 24;10(1):1125.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA